Targeted transurethral microwave thermotherapy versus alpha-blockade in benign prostatic hyperplasia: outcomes at 18 months

Djavan, Bob; Seitz, Christian; Roehrborn, Claus G.; Remzi, Mesut; Fakhari, Mitra; Waldert, Matthias; Basharkhah, Ali; Planz, B.; Harik, Mike; Marberger, Michael

doi:10.1016/s0090-4295(00)00854-2

Cited by 38 publications

(12 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…At 6 months, 78, 65 and 84% of the TUMT group had a 50% or more improvement in symptoms, Q max and QoL scores compared with 33, 100 and 40% of the patients receiving terazosin. At 18 months the mean IPSS in both groups remained similar to the 6-month values [43]. Taken as a whole these results suggest alpha blockade should be used in patients requiring rapid relief because it has a fast onset of action.…”

Section: Tumt or Medical Managementsupporting

confidence: 59%

See 1 more Smart Citation

Transurethral microwave thermotherapy for treatment of benign prostatic hyperplasia

Waldert¹,

Djavan²

2004

The Journal of Men's Health & Gender

Self Cite

View full text Add to dashboard Cite

Many urologists have a high regard for the usefulness of transurethral microwave therapy (TUMT) in treating patients with lower urinary tract symptoms caused by benign prostatic hyperplasia. This therapy has been examined clinically in many centers throughout the world. The rationale for its effect on symptoms is unlike many of the other so-called minimally invasive treatment modalities. The improvement in symptoms and voiding function is greater with transurethral microwave thermotherapy than with drug therapy, and the associated morbidity is low. It also offers greater versatility than drug therapy, allowing patients with severe baseline symptoms and small prostates to be treated successfully. In addition, there has been an evolution in the technology of TUMT from low-energy to high-energy application indicating that this technique has a future in the treatment of lower urinary tract symptoms.

show abstract

Section: Tumt or Medical Managementsupporting

confidence: 59%

“…In 10% of patients treated with Prostraton 2.5, a catheter was required for more than a month. With the Targis microwave system a catheter was required for 24 h in 90% of patients [43].…”

Section: Catheterizationmentioning

confidence: 99%

Transurethral microwave thermotherapy for treatment of benign prostatic hyperplasia

Waldert¹,

Djavan²

2004

The Journal of Men's Health & Gender

Self Cite

View full text Add to dashboard Cite

show abstract

Section: Implications For Practicementioning

confidence: 99%

“…If oral medication fails to improve symptoms or if side effects develop, a tissue ablative intervention is offered. There is some evidence to suggest that the benefits offered by minimally invasive interventions are equivalent to those gained from oral medication [287][288][289] and so this could be a popular option for some men.The economic model should be interpreted cautiously because of the assumptions and uncertainties that underpin it. The model suggests that TURP alone or repeated is amongst the more effective strategies although it is not cost-effective in the Markov model.…”

mentioning

confidence: 99%

Systematic review and economic modelling of effectiveness and cost utility of surgical treatments for men with benign prostatic enlargement

Lourenço

Armstrong²,

N’Dow³

et al. 2008

Health Technol Assess

117

View full text Add to dashboard Cite

Systematic review and economic modelling of effectiveness and cost utility of surgical treatments for men with benign prostatic enlargement. Lourenco, T.; Armstrong, N.; N'Dow, J.; Nabi, G.; Deverill, M.; Pickard, R.; Vale, L.; MacLennan, G.; Fraser, C.; McClinton, S.; Wong, S.; Coutts, A.; Mowatt, G.; Grant, A. Published in: Health Technology Assessment Publication date: 2008 Document VersionPublisher's PDF, also known as Version of record Link to publication in Discovery Research Portal Citation for published version (APA):Lourenco, T., Armstrong, N., N'Dow, J., Nabi, G., Deverill, M., Pickard, R., ... Grant, A. (2008). Systematic review and economic modelling of effectiveness and cost utility of surgical treatments for men with benign prostatic enlargement. Health Technology Assessment, 12(35). General rightsCopyright and moral rights for the publications made accessible in Discovery Research Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.• Users may download and print one copy of any publication from Discovery Research Portal for the purpose of private study or research.• You may not further distribute the material or use it for any profit-making activity or commercial gain.• You may freely distribute the URL identifying the publication in the public portal. Take down policyIf you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim. Download date: 12. May. 2018 Health Technology Assessment 2008; Vol. 12: No. 35 Health Technology Assessment NIHR HTA Programme www.hta.ac.uk November 2008 Systematic review and economic modelling of effectiveness and cost utility of surgical treatments for men with benign prostatic enlargement How to obtain copies of this and other HTA Programme reports. An electronic version of this publication, in Adobe Acrobat format, is available for downloading free of charge for personal use from the HTA website (www.hta.ac.uk). A fully searchable CD-ROM is also available (see below).Printed copies of HTA monographs cost £20 each (post and packing free in the UK) to both public and private sector purchasers from our Despatch Agents.Non-UK purchasers will have to pay a small fee for post and packing. For European countries the cost is £2 per monograph and for the rest of the world £3 per monograph.You can order HTA monographs from our Despatch Agents:-fax (with credit card or official purchase order) -post (with credit card or official purchase order or cheque) -phone during office hours (credit card only).Additionally the HTA website allows you either to pay securely by credit card or to print out your order and then post or fax it. NHS libraries can subscribe free of charge. Public libraries can subscribe at a very reduced cost of £100 for each volume (normally comprising 30-40 titles). The commercial subscription rate is £3...

show abstract

“…A comparable study between medical treatment for symptomatic BPH and TUMT was performed by Djavan et al [49]. Alpha-blocker therapy (terazosine) resulted in a faster symptom relief than TUMT treatment, but already at 6 months the TUMT treatment appeared to be superior to a-blocker treatment, which lasted at least up to 18 months.…”

Section: Costsmentioning

confidence: 92%

Nonablative minimally invasive thermal therapies in the treatment of symptomatic benign prostatic hyperplasia

D'ancona¹

2008

Current Opinion in Urology

View full text Add to dashboard Cite

show abstract

Targeted transurethral microwave thermotherapy versus alpha-blockade in benign prostatic hyperplasia: outcomes at 18 months

Cited by 38 publications

References 13 publications

Transurethral microwave thermotherapy for treatment of benign prostatic hyperplasia

Transurethral microwave thermotherapy for treatment of benign prostatic hyperplasia

Systematic review and economic modelling of effectiveness and cost utility of surgical treatments for men with benign prostatic enlargement

Nonablative minimally invasive thermal therapies in the treatment of symptomatic benign prostatic hyperplasia

Contact Info

Product

Resources

About